冠状动脉慢性完全闭塞治疗的定义与临床试验设计原则:CTO-ARC共识建议
为此,CTO学术研究联盟(CTO-ARC)汇集学者、执业医师、研究人员、医学会代表及监管机构(美国FDA),制定CTO干预的方法、终点、生物标志物、参数、数据、材料、流程、程序、评估、工具和技术标准。本文分三部分总结:关键要素与手术定义、终点定义、临床试验设计原则,旨在提高研究结果的可比性和可解释性。
要点
- CTO-PCI随机试验稀少且观察性研究数据矛盾,亟需标准化终点与定义。
- CTO-ARC共识提出三部分:关键要素与手术定义、终点定义、临床试验设计原则。
- 该共识由多学科及监管机构参与制定,旨在提高研究结果可比性与可解释性。
核心结论
- CTO-ARC共识为CTO-PCI研究提供标准化定义和试验设计原则,以改善结果可比性和可解释性。
研究设计与样本
- 由学者、执业医师、研究人员、医学会代表及美国FDA组成的广泛联盟制定共识建议。
主要发现
- 先前研究设计欠佳及终点定义不统一导致结果缺乏一致性和可解释性。
关键数值与推荐
- 共识分三部分:关键要素与手术定义、终点定义、临床试验设计原则。
临床怎么用
- 临床研究应采用CTO-ARC标准化定义和终点,以提高CTO-PCI证据的可比性。
局限性
- 本文为共识建议,未提供具体随机试验数据或疗效比较结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past 2 decades, chronic total occlusion (CTO) percutaneous coronary intervention has developed into its own subspecialty of interventional cardiology. Dedicated terminology, techniques, devices, courses, and training programs have enabled progressive advancements. However, only a few randomized trials have been performed to evaluate the safety and efficacy of CTO percutaneous coronary intervention. Moreover, several published observational studies have shown conflicting data. Part of the paucity of clinical data stems from the fact that prior studies have been suboptimally designed and performed. The absence of standardized end points and the discrepancy in definitions also prevent consistency and uniform interpretability of reported results in CTO intervention. To standardize the field, we therefore assembled a broad consortium comprising academicians, practicing physicians, researchers, medical society representatives, and regulators (US Food and Drug Administration) to develop methods, end points, biomarkers, parameters, data, materials, processes, procedures, evaluations, tools, and techniques for CTO interventions. This article summarizes the effort and is organized into 3 sections: key elements and procedural definitions, end point definitions, and clinical trial design principles. The Chronic Total Occlusion Academic Research Consortium is a first step toward improved comparability and interpretability of study results, supplying an increasingly growing body of CTO percutaneous coronary intervention evidence.
引用
- Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation. 2021. PMID: 33523728. doi:10.1161/CIRCULATIONAHA.120.046754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。